Alfuzosin
- TRADE NAME: Uroxatral (Sanofi-Aventis); Xatral
- INDICATIONS: Benign prostatic hyperplasia
- CLASS: Adrenergic alpha-receptor antagonist
- HALF-LIFE: 10 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amitriptyline, Atazanavir, Atenolol, Boceprevir, Cimetidine, Citalopram, Conivaptan, Degarelix, Delavirdine, Diltiazem, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Levofloxacin, Lopinavir, Moxifloxacin, Ritonavir, Tadalafil, Telaprevir, Telithromycin, Vorinostat, Ziprasidone
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
GENITOURINARY
HEMATOLOGIC
OCULAR
OTHER
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric